Marker Therapeutics, Inc. (MRKR) Form 10-Q — May 15, 2026
Marker Therapeutics reported a net loss of $3.2 million for the quarter ended March 31, 2026, driven by $4.1 million in operating expenses partially offset by $0.75 million in grant income. The company holds approximately $15.6 million in cash and restricted cash, with working capital of $13.8 million. Management explicitly stated that these factors raise substantial doubt regarding the company’s ability to continue as a going concern. They anticipate funding operations only into the first quarter of 2027 unless additional capital is raised or further grant funds are received.
Key figures
- Total Assets
- 17434008
- Cash Position
- 14915519
- Shares Outstanding
- 16673127
- Cash Burn Qo Q
- 1404192
- Grant Income
- 751691
- Working Capital
- 13795958
- Authorized Shares
- 130000000
- Operating Expenses
- 4072535
Price after filing
Close on the filing date to close N calendar days later (from $1.46). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.